New anticancer compounds
could boost effectiveness of standard therapies
Lixte is developing new drug candidates that could safely bolster the effectiveness of chemotherapy and radiation and treat several diseases.
November 2013: "Biopharma Dealmakers", Nature Biotechnology, pg. 14-15 Click here to download PDF
Lixte Biotechnology Holdings, Inc. is publicly traded as LIXT.